

Pashtoon Murtaza Kasi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4870620/pashtoon-murtaza-kasi-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

2,973
citations

22
h-index

52
g-index

189
ext. papers

4,312
ext. citations

3.9
avg, IF

5.86
L-index

#	Paper	IF	Citations
164	Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. 2022 , 10,		1
163	Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100298	3.6	0
162	A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS214-TPS214	2.2	1
161	Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response to immunotherapy (IO) in patients with pancreatic cancer (PC)?. <i>Journal of Clinical Oncology</i> , 2022 , 40, 607-607	2.2	1
160	Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 56-56	2.2	1
159	Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 517-517	2.2	1
158	The role of serial analysis of hepatocellular carcinoma via circulating tumor DNA in identification of new actionable alterations.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 478-478	2.2	
157	A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research ConsortiumBTCRC-GI15-015.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 283-283	2.2	
156	Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 6-6	2.2	
155	Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 647-647	2.2	
154	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100181	3.6	2
153	Beyond Circulating Tumor Cell Enumeration: Cell-Based Liquid Biopsy to Assess Protein Biomarkers and Cancer Genomics Using the RareCyte Platform.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 835727	5.6	1
152	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102453	2.2	2
151	BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. <i>BMJ Open</i> , 2022 , 12, e060342 ³		0
150	Deploying an artificial intelligence-based online search tool to increase patients' access to and understanding of solid tumor gastrointestinal clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 2045-2051	2.8	
149	Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2021 , 26, 569-578	5.7	5
148	Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2021 , 149, 378-386	7.5	3

147	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 313-319	19.4	59
146	Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3040-3040	2.2	1
145	Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4103-4103	2.2	2
144	Sepsis and pancreatic cancer: Biliary stents a significant risk factor in patients undergoing chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 399-399	2.2	
143	Resection rate of locally advanced pancreatic cancer in gemcitabine plus nab-paclitaxel versus FOLFIRINOX.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 381-381	2.2	
142	Microsatellite Instability-High, Malignant Insulinoma With Brain Metastasis. <i>Cureus</i> , 2021 , 13, e16969	1.2	1
141	BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. <i>BMJ Open</i> , 2021 , 11, e04783		2
140	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. <i>Frontiers in Oncology</i> , 2021 , 11, 736620	5.3	3
139	Circulating tumor DNA in identifying resistant subclones post EGFR blockade: Implications for EGFR rechallenge.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 131-131	2.2	
138	Deploying an AI-based online search tool to increase patients' access to and understanding of solid tumor GI clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 456-456	2.2	1
137	Comparative landscape of actionable somatic alterations in advanced cholangiocarcinoma from circulating tumor and tissue-based DNA profiling.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 342-342	2.2	3
136	BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020 , 11, 236-241	2.8	1
135	Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer. <i>Frontiers in Pharmacology</i> , 2020 , 11, 23	5.6	3
134	23 Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer 2020 , 8, A22-A22		2
133	Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4108-4108	2.2	3
132	Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4541-4541	2.2	2
131	Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4572-4572	2.2	3
130	Serum glycoproteomic-based liquid biopsy for the detection of pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 763-763	2.2	2

129	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020 , 11, 1749-1757	3.3	12
128	Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 362-362	2.2	
127	A phase II trial of pharmacological ascorbate, gemcitabine, and nabpaclitaxel for metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS791-TPS791	2.2	
126	Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS276-TPS276	2.2	0
125	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 6505-6512	12.9	15
124	Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5065-5071	3.1	4
123	Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies. <i>Case Reports in Oncology</i> , 2020 , 13, 941-947	1	5
122	Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2020 , 18, 17	2.3	3
121	Circulating tumor DNA and plasma microsatellite instability during PD-1 blockade. <i>Journal of Gastrointestinal Oncology</i> , 2020 , 11, 826-828	2.8	3
120	Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer. <i>Clinical Case Reports (discontinued)</i> , 2019 , 7, 1729-1734	0.7	2
119	Colorectal cancer. <i>Lancet, The</i> , 2019 , 394, 1467-1480	40	1051
118	Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. <i>Npj Precision Oncology</i> , 2019 , 3, 19	9.8	17
117	Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019 , 18, 1533033819873924	2.7	7
116	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018. <i>Frontiers in Oncology</i> , 2019 , 9, 358	5.3	5
115	Expanding the Indication for Novel Theranostic ¹⁷⁷ Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer. <i>Case Reports in Oncology</i> , 2019 , 12, 98-103	1	7
114	Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 400-406	2.8	8
113	Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation. <i>Journal of Oncology</i> , 2019 , 2019, 5796108	4.5	9
112	Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence. <i>Frontiers in Oncology</i> , 2019 , 9, 46	5.3	2

111	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. <i>Frontiers in Oncology</i> , 2019 , 9, 76	5.3	19
110	Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). <i>Journal of Robotic Surgery</i> , 2019 , 13, 175-179	2.9	4
109	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 745-750	2.8	11
108	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019 , 25, 7035-7045	12.9	72
107	Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions. <i>Current Colorectal Cancer Reports</i> , 2019 , 15, 112-121	1	8
106	A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4070-4070	2.2	1
105	Characteristics and outcomes of patients with colorectal cancer and bone metastasis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15063-e15063	2.2	1
104	BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15065-e15065	2.2	1
103	Landscape of circulating tumor DNA and tissue-based profiling in advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 291-291	2.2	1
102	Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. <i>Drugs of Today</i> , 2019 , 55, 683-693	2.5	6
101	Circulating tumor DNA testing and research in patients with gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 525-525	2.2	
100	Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 289-289	2.2	
99	Impact of obesity upon the survival of cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 288-288	2.2	0
98	A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 619-619	2.2	
97	Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 660-660	2.2	
96	Pharmacogenomics-guided chemotherapy and supportive care for patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 703-703	2.2	
95	Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15067-e15067	2.2	
94	Blood-based next-generation sequencing analysis of neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4110-4110	2.2	

93	Circulating tumor DNA analysis of neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15698-e15698		
92	Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3566-3566	2.2	
91	Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15066-e15066	2.2	
90	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-9	3.6	17
89	Disparities in minimally invasive surgery for colorectal cancer in Florida. <i>American Journal of Surgery</i> , 2019 , 218, 293-301	2.7	8
88	Rising Proportion of Young Individuals With Rectal and Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e87-e95	3.8	56
87	Trends and outcomes of sphincter-preserving surgery for rectal cancer: a national cancer database study. <i>International Journal of Colorectal Disease</i> , 2019 , 34, 239-245	3	8
86	A Care Process Model to Deliver Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2018 , 8, 663	5.3	2
85	Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	10
84	Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. <i>Pancreas</i> , 2018 , 47, e2	2.6	3
83	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018 , 24, 3014-3025	12.9	37
82	BRCA Mutation and Its Association With Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e647-e650	3.8	16
81	Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications. <i>SAGE Open Medical Case Reports</i> , 2018 , 6, 2050313X18786405	0.7	4
80	Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2401-2409	27.4	222
79	Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4089-4089	2.2	1
78	Rising proportion of young individuals with rectal and colon cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13575-e13575	2.2	1
77	Body mass index and long-term outcomes in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15631-e15631	2.2	2
76	Impact of tumor location and variables associated with overall survival in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15651-e15651	2.2	2

75	Feasibility and clinical value of circulating tumor DNA testing in patients with gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16045-e16045	2.2	2
74	Integrating comprehensive point of care and preemptive pharmacogenomic testing for patients with gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18935-e18935	2.2	1
73	Feasibility and value of incorporating pharmacogenomic testing for genetic variants in UGT1A1 and DPYD genes in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 814-814	2.2	3
72	Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues. <i>Drugs of Today</i> , 2018 , 54, 423-432	2.5	2
71	Germline BRCA1/2, PALB2, and ATM mutations in 3,030 patients with pancreatic adenocarcinoma: Survival analysis of carriers and noncarriers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 280-280	2.2	
70	Colorectal cancer characteristics and outcomes after solid organ transplantation.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24131-e24131	2.2	
69	Incidence of pathogenic variants in individuals with a personal or family history of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1589-1589	2.2	
68	Patient and tumor-related factors for sphincter-preserving surgery in patients with rectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15628-e15628	2.2	
67	Genotype-driven dosing of irinotecan and adverse events in patients receiving irinotecan with UGT1A1 gene variants.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15544-e15544	2.2	
66	Simultaneous Glucagon and Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors in a Patient With Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review. <i>Pancreas</i> , 2018 , 47, e1-e2	2.6	1
65	Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 620	5.3	21
64	Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1309	5.6	7
63	Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 330	5.3	2
62	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. <i>Drugs</i> , 2018 , 78, 737-745	12.1	17
61	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017 , 25, 833-838	3.9	6
60	Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency or microsatellite instability in patients with colorectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 747-748	2.8	9
59	BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2624-2630	2.2	176
58	Neuroendocrine Tumor Involving the Epicardium. <i>Case Reports in Oncology</i> , 2017 , 10, 1144-1149	1	1

57	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. <i>Frontiers in Oncology</i> , 2017 , 7, 121	5.3	31
56	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3535-3535	2.2	4
55	Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 199-204	2.2	24
54	Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. <i>BMC Cancer</i> , 2016 , 16, 52	4.8	53
53	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 651-8	6.9	84
52	Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy. <i>Medical Hypotheses</i> , 2016 , 86, 129-31	3.8	1
51	Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. <i>Case Reports in Oncology</i> , 2016 , 9, 33-8	1	3
50	Patterns of palliative care utilization and end of life care in adult patients with cancer who died as inpatients at Mayo Clinic.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21681-e21681	2.2	
49	A case series of sarcoma brain metastases (SBM): A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e22536-e22536	2.2	1
48	Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15124-e15124	2.2	
47	Patterns of palliative care utilization and end-of-life care in adult patients with cancer who died as inpatients at Mayo Clinic.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 60-60	2.2	
46	Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation. <i>Journal of Oncology Practice</i> , 2016 , 12, e88-94	3.1	7
45	Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. <i>Leukemia Research Reports</i> , 2016 , 5, 7-10	0.6	11
44	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. <i>BMC Cancer</i> , 2016 , 16, 4674.8	4.8	43
43	Factors influencing treatment adherence and discontinuation in women with breast cancer. <i>Breast Cancer Management</i> , 2015 , 4, 25-31	0.7	
42	BRCA2-associated pancreatic cancer and current screening guidelines. <i>Cancer</i> , 2015 , 121, 3046	6.4	3
41	Should Vital Signs Be Routinely Obtained Prior to Intravenous Chemotherapy? Results From a 2-Center Study. <i>Cancer Control</i> , 2015 , 22, 515-9	2.2	
40	Nelarabine associated myotoxicity and rhabdomyolysis. <i>Case Reports in Hematology</i> , 2015 , 2015, 825670.7	0.7	2

39	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2015 , 2015, 420159	0.9	4
38	MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. <i>PLoS ONE</i> , 2015 , 10, e0122375	3.7	11
37	A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14028-e14028	2.2	1
36	Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model. <i>PLoS ONE</i> , 2014 , 9, e93694	3.7	7
35	Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. <i>Cancer</i> , 2014 , 120, 3902-13	6.4	30
34	Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection. <i>ISRN Gastroenterology</i> , 2014 , 2014, 764540		11
33	The use of intravenous neostigmine in palliation of severe ileus. <i>Case Reports in Gastrointestinal Medicine</i> , 2013 , 2013, 796739	0.6	4
32	Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia. <i>Case Reports in Hematology</i> , 2013 , 2013, 146938	0.7	6
31	Clinical manifestations and diagnostic challenges in acute porphyrias. <i>Case Reports in Hematology</i> , 2013 , 2013, 628602	0.7	5
30	Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. <i>PLoS ONE</i> , 2013 , 8, e78343	3.7	21
29	Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. <i>Critical Care</i> , 2012 , 16, 231	10.8	98
28	Proposing the use of hyponatremia as a marker to help identify high risk individuals for lung cancer. <i>Medical Hypotheses</i> , 2012 , 79, 327-8	3.8	6
27	Coping styles in patients with anxiety and depression 2012 , 2012, 128672		32
26	The role of fine-needle aspiration cytology in the diagnosis of Basal cell carcinoma. <i>ISRN Dermatology</i> , 2012 , 2012, 132196		7
25	Correlates of morbidity and mortality in severe necrotizing pancreatitis. <i>ISRN Surgery</i> , 2012 , 2012, 215193		13
24	Aortic dissection and renal failure in a patient with severe hypothyroidism. <i>Case Reports in Medicine</i> , 2012 , 2012, 842562	0.7	2
23	Rituximab and cytokine release syndrome. <i>Case Reports in Oncology</i> , 2012 , 5, 134-41	1	28
22	Clinical manifestations and distribution of cutaneous leishmaniasis in pakistan. <i>Journal of Tropical Medicine</i> , 2011 , 2011, 359145	2.4	17

21	Thrombotic thrombocytopenic purpura and gemcitabine. <i>Case Reports in Oncology</i> , 2011 , 4, 143-8	1	6
20	Birt-hogg-dubé syndrome: answering questions raised by a case report published in 1962. <i>Case Reports in Oncology</i> , 2011 , 4, 363-6	1	3
19	Gallbladder agenesis. <i>Case Reports in Gastroenterology</i> , 2011 , 5, 654-62	1	33
18	Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. <i>Case Reports in Medicine</i> , 2011 , 2011, 952584	0.7	14
17	Malignant Hyperthermia and Idiopathic HyperCKemia. <i>Case Reports in Medicine</i> , 2011 , 2011, 194296	0.7	6
16	Incidence, management, and outcome of molar pregnancies at a tertiary care hospital in quetta, pakistan. <i>ISRN Obstetrics & Gynecology</i> , 2011 , 2011, 925316		4
15	Quintuplets born to a woman without fertility treatment in Pakistan. <i>Fertility and Sterility</i> , 2008 , 90, 2007-817-20		20
14	Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan. <i>PLoS Neglected Tropical Diseases</i> , 2008 , 2, e259	4.8	86
13	Vector control in cutaneous leishmaniasis of the old world: a review of literature. <i>Dermatology Online Journal</i> , 2008 , 14, 1	1	7
12	Excessive work hours of physicians in training: maladaptive coping strategies. <i>PLoS Medicine</i> , 2007 , 4, e279	11.6	8
11	Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan. <i>Tropical Doctor</i> , 2007 , 37, 43-5	0.9	29
10	Epilepsy: public knowledge and attitude in a slum area of Karachi, Pakistan. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2007 , 16, 330-7	3.2	27
9	Using choriocarcinoma to cause remission of other tumors: a novel approach to kill tumors. <i>Medical Hypotheses</i> , 2007 , 68, 717	3.8	
8	Studying the association between postgraduate trainees' work hours, stress and the use of maladaptive coping strategies. <i>Journal of Ayub Medical College, Abbottabad: JAMC</i> , 2007 , 19, 37-41	0.3	6
7	Acute health effects of the Tasman Spirit oil spill on residents of Karachi, Pakistan. <i>BMC Public Health</i> , 2006 , 6, 84	4.1	48
6	Psychiatric health laws in Pakistan: from lunacy to mental health. <i>PLoS Medicine</i> , 2005 , 2, e317	11.6	19
5	Diagnosis of cutaneous leishmaniasis by fine needle aspiration cytology: a report of 66 cases. <i>Tropical Doctor</i> , 2005 , 35, 50-1	0.9	5
4	Blinding trachoma: a disease of poverty. <i>PLoS Medicine</i> , 2004 , 1, e44	11.6	24

3	Improvement of water and sanitation for developing countries. <i>Lancet, The</i> , 2004 , 363, 899-900	40	1
2	Trachoma still ignored in developing countries. <i>Lancet, The</i> , 2004 , 363, 1736	40	6
1	Fine-needle aspiration cytology in the diagnosis of cutaneous leishmaniasis. <i>Annals of Saudi Medicine</i> , 2004 , 24, 93-7	1.6	14